Evaluation of 219 Patients with Chronic Hepatitis C Receiving Pegylated Interferon

Aykin N., Cevik F. C., Naz H., Korkmaz P., US T.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.19, sa.2, ss.71-75, 2013 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.4274/vhd.77486
  • Dergi Adı: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.71-75
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: In chronic hepatitis C (CHC) treatment, consensus guidelines recommend the use of either pegylated interferon (PEG-IFN) alfa 2a(40 KD), or PEG-IFN alfa 2b(12 KD) both plus ribavirin for treatment of chronic hepatitis C virus (HCV) infection. The aim of this study was to evaluate treatments of CHC in our patients retrospectively.